ONCT Stock - Oncternal Therapeutics, Inc.
Unlock GoAI Insights for ONCT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $785,000 | $1.49M | $4.32M | $3.38M | $2.42M |
| Gross Profit | $-28,968,000 | $1.31M | $4.15M | $-8,625,000 | $-7,734,000 |
| Gross Margin | -3690.2% | 88.0% | 96.1% | -255.6% | -318.9% |
| Operating Income | $-41,714,000 | $-44,947,000 | $-31,366,000 | $-17,542,000 | $-33,108,000 |
| Net Income | $-39,479,000 | $-43,393,000 | $-31,300,000 | $-17,209,000 | $-15,912,000 |
| Net Margin | -5029.2% | -2912.3% | -725.4% | -509.9% | -656.2% |
| EPS | $-13.43 | $-16.50 | $-1.94 | $-0.69 | $-30.81 |
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
Visit WebsiteEarnings History & Surprises
ONCTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2024 | Nov 6, 2024 | $-3.22 | $-2.86 | +11.2% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-3.03 | $-2.89 | +4.6% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-2.88 | $-2.83 | +1.7% | ✓ BEAT |
Q1 2024 | Mar 7, 2024 | $-3.09 | $-3.11 | -0.6% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-3.00 | $-3.40 | -13.3% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-3.40 | $-3.00 | +11.8% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-4.20 | $-4.00 | +4.8% | ✓ BEAT |
Q1 2023 | Mar 9, 2023 | $-4.40 | $-4.00 | +9.1% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-4.80 | $-4.20 | +12.5% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-4.60 | $-4.60 | 0.0% | = MET |
Q2 2022 | May 5, 2022 | $-3.80 | $-4.00 | -5.3% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-5.00 | $-3.20 | +36.0% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-3.20 | $-3.80 | -18.7% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-2.80 | $-3.20 | -14.3% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-2.00 | $-2.40 | -20.0% | ✗ MISS |
Q1 2021 | Mar 11, 2021 | $-3.60 | $-1.80 | +50.0% | ✓ BEAT |
Q4 2020 | Nov 4, 2020 | $-6.00 | $-4.40 | +26.7% | ✓ BEAT |
Q3 2020 | Aug 6, 2020 | — | $-6.80 | — | — |
Q2 2020 | May 7, 2020 | — | $-6.20 | — | — |
Q1 2020 | Mar 16, 2020 | — | $-5.40 | — | — |
Latest News
Frequently Asked Questions about ONCT
What is ONCT's current stock price?
What is the analyst price target for ONCT?
What sector is Oncternal Therapeutics, Inc. in?
What is ONCT's market cap?
Does ONCT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ONCT for comparison